Yki-Järvinen H, Koivisto V A
J Clin Endocrinol Metab. 1984 Sep;59(3):371-8. doi: 10.1210/jcem-59-3-371.
Tissue sensitivity to insulin (euglycemic insulin clamp technique), hepatic glucose production (3-[3H]glucose infusion) and insulin binding to erythrocyte receptors were studied in 14 newly diagnosed type 1 diabetic patients after the disappearance of ketosis and after 3 months of insulin therapy. The control group consisted of 14 normal subjects. During the two insulin clamp studies, plasma glucose in the diabetic patients was maintained at 5.0 +/- 0.04 (SEM) mmol/liter and 4.9 +/- 0.05 mmol/liter, with corresponding steady state free insulin levels of 90 +/- 4 mU/liter, and 67 +/- 6 mU/liter (P less than 0.02) during the first and second study, respectively. The decline in free insulin levels was due to the development of insulin antibodies during insulin therapy (10 +/- 0.1% vs. 18 +/- 2%, P less than 0.001, serum insulin-binding capacity during the first and second study, respectively). In the normal subjects, steady state plasma glucose and insulin levels were 4.9 +/- 0.1 mmol/liter and 89 +/- 4 mU/liter, respectively. The rate of glucose metabolism (M) in the diabetic patients during the first study (5.13 +/- 0.65 mg/kg X min) was 35% lower than that in the normal subjects (7.94 +/- 0.50 mg/kg X min, P less than 0.005). After 3 months of insulin therapy, M increased by 35% to 6.92 +/- 0.58 mg/kg X min, which was comparable to that in the normal subjects. To compensate for the difference in plasma free insulin levels, we calculated an index for insulin sensitivity by dividing M by the ambient insulin concentration (I). During the 3 months of insulin therapy, M/I rose 2-fold to 11.63 +/- 1.10 mg/kg X min per mU insulin/liter X 100, which was similar to that in normal subjects (9.16 +/- 0.67 mg/kg X min per mU insulin/liter X 100). Five diabetic patients had a partial clinical remission, as determined by normal fasting C-peptide levels. In these patients, insulin sensitivity was 35-50% greater than in those who failed to have a remission (P less than 0.05). Basal hepatic glucose production in the diabetic patients during the first study (2.78 +/- 0.14 mg/kg X min) was 56% higher than in the normal subjects (1.78 +/- 0.04 mg/kg X min, P less than 0.001), and remained unchanged during insulin therapy. During the hyperinsulinemia induced by the clamp, hepatic glucose production was totally suppressed in both the diabetic and control subjects.(ABSTRACT TRUNCATED AT 400 WORDS)
对14例新诊断的1型糖尿病患者在酮症消失后及胰岛素治疗3个月后,研究了组织对胰岛素的敏感性(正常血糖胰岛素钳夹技术)、肝脏葡萄糖生成(3 - [3H]葡萄糖输注)以及胰岛素与红细胞受体的结合情况。对照组由14名正常受试者组成。在两次胰岛素钳夹研究期间,糖尿病患者的血浆葡萄糖分别维持在5.0±0.04(标准误)mmol/升和4.9±0.05 mmol/升,第一次和第二次研究期间相应的稳态游离胰岛素水平分别为90±4 mU/升和67±6 mU/升(P<0.02)。游离胰岛素水平的下降是由于胰岛素治疗期间胰岛素抗体的产生(第一次和第二次研究期间血清胰岛素结合能力分别为10±0.1%对18±2%,P<0.001)。在正常受试者中,稳态血浆葡萄糖和胰岛素水平分别为4.9±0.1 mmol/升和89±4 mU/升。糖尿病患者在第一次研究期间的葡萄糖代谢率(M)(5.13±0.65 mg/kg·min)比正常受试者(7.94±0.50 mg/kg·min,P<0.005)低35%。胰岛素治疗3个月后,M增加35%至6.92±0.58 mg/kg·min,与正常受试者相当。为补偿血浆游离胰岛素水平的差异,我们通过将M除以周围胰岛素浓度(I)计算胰岛素敏感性指数。在胰岛素治疗的3个月期间,M/I升高2倍至11.63±1.10 mg/kg·min per mU胰岛素/升×100,与正常受试者(9.16±0.67 mg/kg·min per mU胰岛素/升×100)相似。5例糖尿病患者经空腹C肽水平正常判定为部分临床缓解。在这些患者中,胰岛素敏感性比未缓解的患者高35% - 50%(P<0.05)。糖尿病患者在第一次研究期间的基础肝脏葡萄糖生成(2.78±0.14 mg/kg·min)比正常受试者(1.78±0.04 mg/kg·min,P<0.001)高56%,且在胰岛素治疗期间保持不变。在钳夹诱导的高胰岛素血症期间,糖尿病和对照组受试者的肝脏葡萄糖生成均被完全抑制。(摘要截断于400字)